ClinicalTrials.gg
CompletedNCT02528643Updated Dec 6, 2024Results posted

A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Enzalutamide and Placebo in Advanced Hepatocellular Carcinoma, sponsored by Astellas Pharma Global Development, Inc.. Completed at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Enrollment
131st of 775
165 · median 36
Started
2015
with 35 others
Phase 2
259 of 926
40 open now
Registered
426th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 131st largest by enrollment of the 775 interventional ones that give a count, is one of 36 that started in 2015, is one of 259 in phase 2, and was the 426th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS).

This study also evaluated the safety of enzalutamide; pharmacokinetics of enzalutamide and the active metabolite N-desmethyl and Progression Free Survival (PFS) of enzalutamide as compared to placebo in participants with advanced HCC.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma

Keywords

  • MDV3100
  • advanced hepatocellular carcinoma
  • enzalutamide
  • Xtandi
  • ASP9785
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 18 years of age or is considered an adult according to local regulation at the time of signing .
  • Subject has a documented diagnosis of advanced HCC of any etiology.
  • Subject has BCLC stage B or C.
  • Subject's lesions are not amenable to local therapies which may be beneficial, such as transarterial chemoembolization (TACE), radiofrequency ablation, radiotherapy, etc., and the subject is not a candidate for any curative treatments such as resection or liver transplant.
  • Subject has hepatic function status of Class A at Screening.
  • Subject received prior systemic treatment for HCC with sorafenib or other anti-VEGF therapy and had confirmed disease progression or discontinued treatment due to a drug-related toxicity. Subject may have received 1 before or after sorafenib/anti-VEGF treatment.
  • Subject has adequately recovered from toxicities due to prior HCC therapy to ≤ grade 1.
  • Subject has an performance status ≤ 1 at Screening and on Day 1.
  • Subject has available formalin-fixed, paraffin-embedded tumor specimen with adequate viable tumor cells in a tissue block or unstained serial slides accompanied by an associated pathology report prior to enrollment. Archival or fresh tissue is required.
  • Subject has an estimated of at least 3 months on Day 1, in the opinion of the investigator.
  • Female subject is either:

    • Not of : (defined as no spontaneous menses for at least 12 consecutive months prior to Screening with follicle-stimulating hormone [FSH] > 40 IU/L for women \< 55 years of age at Screening), or documented to be surgically sterile or status posthysterectomy (at least 1 month prior to Screening).
    • Or, if of childbearing potential: must have a negative urine pregnancy test at Screening and on Day 1 before the first dose of study drug is administered, and must use 2 acceptable methods of * if sexually active from Screening through 3 months after the last dose of study drug.
  • Sexually active male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control from Screening through 3 months after the last dose of study drug.

    * Two acceptable methods of birth control are as follows:

    • Condom (barrier method of contraception); AND
    • One of the following is required: Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female subject or female partner of a male subject; Additional barrier method: contraceptive sponge or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female subject or female partner of a male subject. For male subject or male partner of female subject, vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy) performed at least 6 months before Screening. Tubal ligation in the female partner of a male subject performed at least 6 months before Screening. Established and ongoing use of oral, injected, or implanted hormonal contraceptive by female partner of a male subject.
  • Female subject must not be breastfeeding at Screening or during the study period and for 3 months after final study drug administration.
  • Subject must agree not to donate sperm or ova from first dose of study drug through 3 months after the last dose of study drug.
  • Throughout the study, male subject must use a condom if having sex with a pregnant woman.
  • Subject must be able to swallow study drug and comply with study requirements.
  • Subject agrees not to participate in another interventional study while on treatment.
  • Received double-blind enzalutamide study treatment during the main study.

Exclusion criteria

Exclusion Criteria:

  • Subject has a severe concurrent disease, infection or comorbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment.
  • Subject has fibrolamellar variant of HCC.
  • Subject has status of Class B or C at Screening.
  • Subject has a history of organ allograft including liver transplant.
  • Subject has uncontrolled symptomatic ascites.
  • Subject has known or suspected or active .
  • Subject has a history of a non-HCC with the following exceptions:

    • The subject with a previous history of a noninvasive carcinoma is eligible if in the opinion of the investigator he/she has had successful curative treatment any time prior to Screening and requires no further therapy for the malignancy.
    • For all other malignancies, the subject is eligible if he/she has undergone potentially curative therapy and has been considered disease free for at least 3 years prior to Screening.
  • Subject has inadequate marrow, hepatic, and/or renal function at the Screening Visit defined as:

    • \< 1.5 x109/L (\< 1500 cells/mm3)
    • count \< 50 x109/L (\< 50,000 cells/mm3)
    • \< 8.5 g/dL (\< 5.3 mmol/L)
    • > 1.7
    • Albumin \< 2.8 g/dL (\< 28 g/L)
    • Total (TBL) > 2 x
    • or ALT > 5 x ULN
    • Creatinine > 1.5 x ULN
    • Note: Transfusions/infusions to meet eligibility criteria are not allowed but if in the opinion of the Principal Investigator, it is beneficial, the patient may be rescreened after receiving one of these procedures.
  • Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma, encephalopathy within 3 months of Day 1).
  • Subject has a history of bleeding esophageal varices within 3 months before the Day 1 visit.
  • Subject has a history of loss of consciousness or within 12 months before the Day 1 visit.
  • Subject has cardiovascular disease including:

    • Myocardial infarction within 6 months before the Day 1 visit.
    • Uncontrolled angina within 6 months before the Day 1 visit.
    • Congestive heart failure (NYHA) Class III or IV or history of congestive heart failure NYHA Class III or IV in the past, unless a Screening echocardiogram or multi-gated acquisition scan performed within 3 months before the Day 1 visit reveals a that is ≥ 45%.
    • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, Torsade de Pointes).
    • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place.
    • Hypotension as indicated by systolic blood pressure \< 86 mmHg on 2 consecutive measurements at the Screening visit.
    • Bradycardia (in the presence of known cardiovascular disease) as indicated by a heart rate of \< 50 beats per minute on the Screening (ECG) recording.
    • Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg on 2 consecutive measurements at the Screening visit.
  • Subject has a gastrointestinal disorder affecting absorption.
  • Subject had previous local therapy (e.g., surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) within 14 days prior to Day 1, has not recovered from toxicities from prior local therapy or may require major surgical procedure during the course of the study.
  • Subject has received chemotherapy, immunotherapy or any other systemic anticancer therapy (including sorafenib) or any other drug within 14 days prior to the Day 1 visit.
  • Subject has received an agent that either blocks androgen synthesis or targets the AR (e.g., abiraterone acetate, bicalutamide, enzalutamide, ARN-509 or other investigational AR signaling inhibitors). The exception of spironolactone is allowed after Medical Monitor consultation.
  • Subject has used any of the following within 28 days before the Day 1 visit:

    • 5-α reductase inhibitors
    • Systemic androgens and estrogens (vaginal estrogen creams are allowed)
    • Herbal therapies, with an antitumor effect.
  • Subject has a known history of positive test for .
  • Subject has shown a reaction to the active pharmaceutical ingredient or any of the enzalutamide capsule components, including caprylocaproyl polyoxylglycerides (Labrasol), butylated hydroxyanisole and butylated hydroxytoluene.
  • Subject has addictive/substance abuse problems.
  • Subject has any other condition or reason that, in the opinion of the investigator, interferes with the ability of the subject to participate in the trial, places the subject at undue risk or complicates the interpretation of safety data.
  • Received double-blind placebo during the main study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Enzalutamide 160 mg

    Participants received enzalutamide 160 milligrams (mg) capsules, orally QD during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Eligible participants received enzalutamide 160 mg capsules, orally QD during open label period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.

    Drug: Enzalutamide

  • Placebo comparator
    Placebo

    Participants received enzalutamide matching placebo orally, once daily (QD) during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.

    Drug: Placebo

Interventions

  • Oral capsule

    Also known as: MDV3100, Xtandi

  • DrugPlacebo

    Oral capsule

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the documented date of death from any cause. Participants who were still alive at the time of the data cut-off date was censored on the last date known to be alive or at the data cutoff date, whichever occurs first. Results based on Kaplan-Meier estimates.

    Time frame: From date of randomization up to data cut-off date 02 Oct 2017 (approximately 22 months); median follow-up time was 14.65 months for enzalutamide and 13.83 for placebo.

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug up to 30 days after last dose of study drug or initiation of new treatment, whichever comes first. AEs were considered as serious if resulted in in death, was life-threatening resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization and other medically important events.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug median (minimum, maximum) treatment duration was 64.0 (6, 1736) days for enzalutamide and 64.0 (12, 490) for placebo

  2. Plasma Trough Concentrations of Enzalutamide

    Blood samples were collected for analysis.

    Time frame: Predose at weeks 5, 9 and 13

  3. Plasma Trough Concentrations N-desmethyl Enzalutamide (M2 Metabolite)

    Blood samples were collected for analysis.

    Time frame: Predose at weeks 5, 9 and 13

  4. Plasma Trough Concentrations of MDPC0001 (M1 Metabolite)

    Blood samples were collected for analysis.

    Time frame: Predose at weeks 5, 9 and 13

  5. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization until the date of documented radiographic disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator or death from any cause on study, whichever occurred first. The earliest of the censoring times was used: Participants with (1) no evaluable postbaseline imaging assessments or did not die were censored at the randomization date; (2) no radiographical progression or did not die before analysis cutoff date were censored at the last radiological assessment date before analysis cutoff date; (3) with no radiographical progression or did not die before new HCC treatment was censored at the last radiological assessment date before start of new HCC treatment. Based on Kaplan-Meier.

    Time frame: From date of randomization up to data cut-off date 02 Oct 2017 (approximately 22 months); median follow-up time was 14.65 months for enzalutamide and 13.83 for placebo.

07

Results

Posted Nov 20, 2018

Participant flow

Participants were enrolled from 37 sites in 9 countries in Europe, Asia, and North America. Participants with hepatocellular carcinoma (HCC) of any etiology whose disease had progressed on or who were intolerant to sorafenib or other antivascular endothelial growth factor (VEGF) therapy in the advanced setting were enrolled. Double blind treatment (DB) Open label (OL).

DB (Median Duration up to 14.65 Months)
Participant flow — DB (Median Duration up to 14.65 Months)
MilestonePlaceboEnzalutamide
Started55110
Treated55107
Completed00
Not completed55110
Withdrew: Adverse event58
Withdrew: Death16
Withdrew: Lost to follow-up01
Withdrew: Progressive disease4482
Withdrew: Withdrawal by subject28
Withdrew: Miscellaneous35
OL (Median Duration up to 27.56 Months)
Participant flow — OL (Median Duration up to 27.56 Months)
MilestonePlaceboEnzalutamide
Started01
Completed00
Not completed01
Withdrew: Progressive disease01

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the documented date of death from any cause. Participants who were still alive at the time of the data cut-off date was censored on the last date known to be alive or at the data cutoff date, whichever occurs first. Results based on Kaplan-Meier estimates.

Time frame:
From date of randomization up to data cut-off date 02 Oct 2017 (approximately 22 months); median follow-up time was 14.65 months for enzalutamide and 13.83 for placebo.
Reported as:
Median · months
Overall Survival (OS)
monthsPlaceboEnzalutamide
Overall Survival (OS)7.69 (5.82 to 13.77)7.75 (6.05 to 9.92)
Statistical analysis
  • Placebo vs Enzalutamide · Log Rank · p = 0.248 (One-sided p-value.) · Hazard ratio (hr): 1.146 · 95% CI 0.774 to 1.696Calculated using a Cox proportional hazard model, stratified by geographic region and ECOG performance status. Hazard ratio \< 1 indicated a reduction in hazard rate in favor of enzalutamide group.
  • Placebo vs Enzalutamide · Log Rank · p = 0.252 (One-sided p-value.) · Hazard ratio (hr): 1.142 · 95% CI 0.773 to 1.688Calculated using a Cox proportional hazard model. Hazard ratio \< 1 indicated a reduction in hazard rate in favor of enzalutamide group.
SecondaryNumber of Participants With Adverse Events (AEs)

Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug up to 30 days after last dose of study drug or initiation of new treatment, whichever comes first. AEs were considered as serious if resulted in in death, was life-threatening resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization and other medically important events.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug median (minimum, maximum) treatment duration was 64.0 (6, 1736) days for enzalutamide and 64.0 (12, 490) for placebo
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPlaceboEnzalutamide
TEAE50105
Drug-related TEAEs2469
Deaths4582
TEAE Leading to Death612
Drug-related TEAEs Leading to Death00
Serious TEAEs2247
Drug-related Serious TEAEs37
TEAEs Leading to Treatment Withdrawal1434
Drug-related TEAEs Leading to Treatment Withdrawal47
SecondaryPlasma Trough Concentrations of Enzalutamide

Blood samples were collected for analysis.

Time frame:
Predose at weeks 5, 9 and 13
Reported as:
Mean · μg/mL
Plasma Trough Concentrations of Enzalutamide
μg/mLEnzalutamide
Week 514.29 ± 4.15
Week 912.15 ± 4.68
Week 1312.45 ± 5.44
SecondaryPlasma Trough Concentrations N-desmethyl Enzalutamide (M2 Metabolite)

Blood samples were collected for analysis.

Time frame:
Predose at weeks 5, 9 and 13
Reported as:
Mean · μg/mL
Plasma Trough Concentrations N-desmethyl Enzalutamide (M2 Metabolite)
μg/mLEnzalutamide
Week 511.01 ± 3.63
Week 912.65 ± 3.89
Week 1312.21 ± 4.94
SecondaryPlasma Trough Concentrations of MDPC0001 (M1 Metabolite)

Blood samples were collected for analysis.

Time frame:
Predose at weeks 5, 9 and 13
Reported as:
Mean · μg/mL
Plasma Trough Concentrations of MDPC0001 (M1 Metabolite)
μg/mLEnzalutamide
Week 54.70 ± 3.86
Week 95.60 ± 5.63
Week 136.12 ± 4.24
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of documented radiographic disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator or death from any cause on study, whichever occurred first. The earliest of the censoring times was used: Participants with (1) no evaluable postbaseline imaging assessments or did not die were censored at the randomization date; (2) no radiographical progression or did not die before analysis cutoff date were censored at the last radiological assessment date before analysis cutoff date; (3) with no radiographical progression or did not die before new HCC treatment was censored at the last radiological assessment date before start of new HCC treatment. Based on Kaplan-Meier.

Time frame:
From date of randomization up to data cut-off date 02 Oct 2017 (approximately 22 months); median follow-up time was 14.65 months for enzalutamide and 13.83 for placebo.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPlaceboEnzalutamide
Progression Free Survival (PFS)1.87 (1.84 to 3.45)2.23 (1.87 to 3.52)
Statistical analysis
  • Placebo vs Enzalutamide · Log Rank · p = 0.396 (One-sided p-value.) · Hazard ratio (hr): 1.039 · 95% CI 0.732 to 1.474Calculated using a Cox proportional hazard model, stratified by ECOG performance status and region. Hazard ratio \< 1 indicated a reduction in hazard rate in favor of enzalutamide group.
  • Placebo vs Enzalutamide · Log Rank · p = 0.586 (One-sided p-value.) · Hazard ratio (hr): 0.959 · 95% CI 0.684 to 1.345Calculated using a Cox proportional hazard model. Hazard ratio \< 1 indicated a reduction in hazard rate in favor of enzalutamide group.

Adverse events

Collected over From first dose of study drug up to 30days after last dose of study drug median (minimum, maximum) treatment duration was 64.0 (6, 1736) days for enzalutamide and 64.0 (12, 490) for placebo. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo45/55 (81.8%)22/55 (40%)46/55 (83.6%)
Enzalutamide82/107 (76.6%)47/107 (43.9%)96/107 (89.7%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPlaceboEnzalutamide
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/5514/107
Abdominal painGastrointestinal disorders1/557/107
AscitesGastrointestinal disorders0/555/107
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/551/107
Renal failure acuteRenal and urinary disorders2/553/107
AnaemiaBlood and lymphatic system disorders1/553/107
AstheniaGeneral disorders0/553/107
Back painMusculoskeletal and connective tissue disorders1/553/107
Abdominal distensionGastrointestinal disorders0/552/107
Upper gastrointestinal haemorrhageGastrointestinal disorders0/552/107
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlaceboEnzalutamide
FatigueGeneral disorders10/5538/107
Decreased appetiteMetabolism and nutrition disorders12/5533/107
NauseaGastrointestinal disorders6/5529/107
DiarrhoeaGastrointestinal disorders13/5513/107
AstheniaGeneral disorders11/5511/107
Abdominal pain upperGastrointestinal disorders9/557/107
Aspartate aminotransferase increasedInvestigations9/5516/107
Abdominal painGastrointestinal disorders8/5515/107
ConstipationGastrointestinal disorders5/5515/107
Weight decreasedInvestigations5/5515/107

Baseline characteristics

Full analysis set (FAS) consisted of all randomized participants regardless of whether or not participants received study drug.

Age, Continuous
Age, Continuous(Years)PlaceboEnzalutamideTotal
Mean62.6 ± 12.563.7 ± 10.963.3 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEnzalutamideTotal
Female61521
Male4995144
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEnzalutamideTotal
Hispanic or Latino033
Not Hispanic or Latino55107162
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEnzalutamideTotal
White265278
Black or African American358
Asian255277
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander011
Other101
Geographic Region
Geographic Region(Participants)PlaceboEnzalutamideTotal
Asia244872
Other316293
Eastern Cooperative Oncology Group (ECOG) PS (0,1)
Eastern Cooperative Oncology Group (ECOG) PS (0,1)(Participants)PlaceboEnzalutamideTotal
ECOG PS = 0234366
ECOG PS = 1326799
08

Study locations

38 sites
  • Site US10003
    San Francisco, California 94115, United States
  • Site US10009
    Skokie, Illinois 60077, United States
  • Site US10017
    Minneapolis, Minnesota 55455-0362, United States
  • Site US10021
    Lebanon, New Hampshire 03756-1000, United States
  • Site US10008
    Portland, Oregon 97239, United States
  • Site US10014
    Philadelphia, Pennsylvania 19104, United States
  • Site US10019
    Philadelphia, Pennsylvania 19104, United States
  • Site US10016
    Milwaukee, Wisconsin 53226-3522, United States
  • Site CA15001
    Toronto, Ontario M5G2C4, Canada
  • Site CA15002
    Montreal, Quebec H3T 1E2, Canada
  • Site CA15003
    Montreal, H4A 3J1, Canada
  • Site HK85202
    Kowloon, 999077, Hong Kong
  • Site HK85204
    Shatin, 999077, Hong Kong
  • Site IT39008
    Rozzano, Milan 20089, Italy
  • Site IT39005
    Benevento, Italy
  • Site IT39006
    Milano, 20122, Italy
  • Site IT39002
    Milan, 20132, Italy
  • Site IT39011
    Padova, 35128, Italy
  • Site IT39004
    Pavia, 27100, Italy
  • Site KR82002
    Seongnam-Si, Gyeonggi-do 013620, Korea, Republic of
  • Site KR82005
    Seoul, Seoul Teugbyeolsi 135-710, Korea, Republic of
  • Site KR82006
    Seoul, 03080, Korea, Republic of
  • Site KR82007
    Seoul, 03722, Korea, Republic of
  • Site KR82004
    Seoul, 05505, Korea, Republic of
  • Site KR82001
    Seoul, 06591, Korea, Republic of
  • Site US10001
    San Juan, 00927, Puerto Rico
  • Site ES34003
    Barcelona, 08035, Spain
  • Site ES34006
    Cordoba, 14004, Spain
  • Site ES34004
    Madrid, 28222, Spain
  • Site TW88603
    Douliu, 640, Taiwan
  • Site TW88606
    Tainan, 704, Taiwan
  • Site TW88605
    Tainan, 710, Taiwan
  • Site TW88604
    Taipei City, 10048, Taiwan
  • Site GB44007
    Birmingham, B15 2WB, United Kingdom
  • Site GB44004
    London, SE5 9RS, United Kingdom
  • Site GB44008
    London, W12 OHS, United Kingdom
  • Site GB44005
    Manchester, M20 4BX, United Kingdom
  • Site GB44002
    Wirral, CH63 4JY, United Kingdom
09

References and documents

Publications

  • Ryoo BY, Palmer DH, Park SR, Rimassa L, Debashis Sarker, Daniele B, Steinberg J, Lopez B, Lim HY. Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. Clin Drug Investig. 2021 Sep;41(9):795-808. doi: 10.1007/s40261-021-01063-0. Epub 2021 Aug 5. Erratum In: Clin Drug Investig. 2022 Mar;42(3):283. doi: 10.1007/s40261-022-01132-y. PubMed 34351608 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Oct 2017, 22 months.

Results were first posted in Nov 2018, 1 year 1 month after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 22 months is below that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2015
First posted
Aug 19, 2015
StartActual
Nov 9, 2015
Primary completionActual
Oct 2, 2017
CompletionActual
Feb 9, 2021
Results first posted
Nov 20, 2018
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02528643
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Aug 19, 2015
Start date
Nov 9, 2015
Primary completion
Oct 2, 2017
Completion
Feb 9, 2021
Results posted
Nov 20, 2018
Last update
Dec 6, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion